Agoracom Blog Home

Archive for the ‘Eyecarrot Innovations Corp’ Category

Eyecarrot $EYC.ca Announces Change of Name to Binovi Technologies Corp and the Postponement of Annual Financial Statements $EYPT $KALA

Posted by AGORACOM-JC at 12:38 PM on Monday, June 29th, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announced that its Board of Directors has approved a name change from Eyecarrot Innovations Corp. to Binovi Technologies Corp.
  • In connection with the name change, the Company’s trading symbol on the TSX Venture Exchange will be changed to ‘VISN’
  • It is expected that the name change will be effected on or about June 30, 2020 and the Company’s common shares will begin trading under the new name and symbol upon market open on Thursday July 2, 2020, subject to final approval by TSXV

June 29, 2020 – Toronto, New York – Eyecarrot Innovations Corp., (Eyecarrot) (TSXV:EYC) | (OTC:EYCCF) | (2EYA:GR) a leader is neuro-vision performance technology, announces that its Board of Directors has approved a name change from Eyecarrot Innovations Corp. to Binovi Technologies Corp. In connection with the name change, the Company’s trading symbol on the TSX Venture Exchange (“TSXV”) will be changed to ‘VISN’. It is expected that the name change will be effected on or about June 30, 2020 and the Company’s common shares will begin trading under the new name and symbol upon market open on Thursday July 2, 2020, subject to final approval by TSXV. The CUSIP number assigned to the Company’s shares following the name change is 09076N109 (ISIN: CA09076N1096). No action is required to be taken by shareholders with respect to the name change. Outstanding share and warrant certificates are not affected by the name change and do not need to be exchanged.

Postponement of Annual Financial Statements

The Company announces the postponement of filing its annual financial statements and management’s discussion and analysis (collectively the “Annual Statements”) for the year ended February 29, 2020 due to logistics and delays caused by the COVID-19 pandemic.

The Company is relying on exemptive relief granted by Canadian securities regulatory authorities that allows it to delay the filing of its Annual Statements required by sections 4.2 and 5.12(2) of National Instrument 51-102 due to be filed by June 29, 2020. In response to the coronavirus disease pandemic, securities regulatory authorities in Canada have granted a blanket exemption allowing issuers an additional 45 days to complete their regulatory filings.

Eyecarrot anticipates that its Annual Statements will be available for filing at its earliest opportunity, which is expected to occur on or before August 12, 2020. Until such time as the Annual Statements are filed, the Company’s management and insiders are subject to a trading blackout that reflects the principals contained in section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

Other than as previously disclosed by the Company in news releases, there have been no material business developments since the date of the last interim financial statements filed on January 30, 2020, copies of which are available under the Company’s profile on SEDAR at www.sedar.com. The Company will be providing an update news release on the status of filing its February 29, 2020 audited financial statements and its May 30, 2020 first quarter unaudited financial statements by July 29, 2020.

AGORACOM Agreement

The Company announces that further to its news release dated April 28, 2020, it will make its first issuance of shares under its online marketing and awareness program with Agora Internet Relations Corp. (“AGORACOM”). Pursuant to this first tranche, the Company will issue 52,154 common shares of the Company at a deemed price of $0.26. AGORACOM’s program includes a “CEO Verified” Discussion Forum. The forum serves as the Company’s primary social media platform to interact with both shareholders and the broader investment community in a fully moderated environment.

The Eyecarrot HUB can be found at https://agoracom.com/ir/EyecarrotInnovations

For additional information on the Company, please visit https://www.eyecarrot.com/investors/

About Binovi by Eyecarrot

Eyecarrot Innovations Corp. is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of cognitive skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

Terry Booth

Executive Chairman

Adam Cegielski

Founder | CEO

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CLIENT FEATURE: Eyecarrot Innovations $EYC.ca Creating Faster Brains Through Stronger Eyes $EYPT $KALA

Posted by AGORACOM-JC at 5:45 PM on Wednesday, June 24th, 2020
http://www.smallcapepicenter.com/eyc%20square.png

EYC: TSX-V

Trusted and used by some of the world’s top professional sports teams, including:

Why Eyecarrot?

  • Eyecarrot Has Already Started Commercializing Its Vision Therapy Platform
  • Company’s Vision Therapy Products Used In:
    • Over 1,500 Practices
    • 20 Countries
  • Flagship “Binovi” Is State-Of-The-Art Platform
    • Measures 14 Key Vision Skills
    • Essential For Maximizing Brain Performance
    • Shipped Over 400 Binovi Units (April 2020)
    • Goal Is 2,500 Binovi Units (End Of 2020)
  • Signed Sports Vision Partnership With Eli Wilson Goaltending
    • World Leader In Goaltending Development
    • 600 Active Goaltending Camp Participants
    • 50,000 Global Aspiring Goaltenders
  • Closed Major Financing In Q1 2020
  • Eyecarrot is now well positioned to further commercialize and capitalize on massive demand for Vision Therapy and Training For Athletes and Education

THE MARKET OPPORTUNITY

  • Vision Therapy captures 3% of a $36B Yearly Vision Market today
  • Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
  • Sights are set on disrupting the sports performance industry in 2020 while receiving engagement from leaders within the human performance – sport performance industry
  • The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
  • Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022

WATCH OUR RECENT INTERVIEW

Eyecarrot Innovations is an advertising client of AGORA Internet Relations Corp.

Eyecarrot $EYC.ca Appoints Dr. Jason Dyck and Dr. Sandra Stoddard to the Scientific Advisory Board $EYPT $KALA

Posted by AGORACOM-JC at 9:07 AM on Thursday, June 11th, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announcd the appointment of Dr. Jason Dyck and the appointment of Dr. Sandra Stoddard to the company’s Scientific Advisory Board

TORONTO, ON and NEW YORK, NY / June 11, 2020 / Eyecarrot Innovations Corp (TSXV:EYC)(QTCQB:EYCCF)(2EYA:GR) is pleased to announce the appointment of Dr. Jason Dyck and the appointment of Dr. Sandra Stoddard to the company’s Scientific Advisory Board.

About Dr. Jason Dyck

Dr. Jason Dyck is a world-class research scientist and professor in the Department of Pediatrics at the University of Alberta, the director of the University of Alberta Cardiovascular Research Centre, a Canada Research Chair in Molecular Medicine, and a fellow of the Canadian Academy of Health Sciences. Dr. Dyck also has a wealth of experience in establishing and directing large interdisciplinary research teams, which provides the strongest foundation for credible and useful research to reach key stakeholders and improve healthcare and health outcomes.

Dr. Dyck has published over 220 peer-reviewed papers and is a recognized expert in basic biomedical research, which has attracted international recognition and has contributed to him being invited to co-chair the National Research Council for Diabetes Canada, and to serve on the Editorial boards of 4 major international journals. Dr. Dyck also reviews grants for international granting bodies such as The National Aeronautics and Space Administration (NASA), the National Institute for Health (NIH), the Welcome Trust, the National Health and Medical Research Council of Australia, the Dutch Diabetes Research Foundation and the European Research Council. Dr. Dyck was recognized as one of Canada’s Top 40 under 40 (awarded by the Caldwell Partners).

“I’m excited by this opportunity to learn from the Eyecarrot team and to assist the science advance to the clinical testing phase for both educational purposes and sports medicine applications. I am impressed with the passion that Adam brings to this company and with this new team that he has assembled. Working alongside Mr. Booth again in this capacity is important because he has the passion, vision and experience to help this company achieve its goals,” stated Dr. Jason Dyck PhD, Eyecarrot Scientific Advisory Board.

Dr. Dyck has a track record of excellence at all levels, and his background in research, leadership, and business development are key attributes that will help drive the scientific backing and product offerings included in the Binovi Platform,” commented Adam Cegielski, Eyecarrot CEO.

As Chief Scientific Officer, I welcome the scientific perspectives of accomplished researchers such as Dr. Dyck”, added Dr. Leonard Press, newly appointed Eyecarrot CSO.

About Dr. Sandra Stoddard

Dr. Sandra Stoddard is a distinguished educator who has devoted her entire 32-year career to ensuring her personal vision: success for all students. For Dr. Stoddard, this is not just a statement, but a passion. She holds a Bachelors of Education, a Masters in Educational Psychology in the area of Mild and Moderate Disabilities and a PhD in Educational Psychology. She was the recipient of the Nadene M. Thomas Graduate Research Bursary for her PhD Dissertation: Predicting First-Year Teaching Proficiency.

Throughout her career, Dr. Stoddard has served in many capacities including teacher, educational consultant, assistant principal, principal, director and executive director. She is currently the Associate Superintendent of a public-school division and oversees Early Learning, Inclusive Learning, Curriculum and Instructional Supports, Information Technologies, as well as all the Elementary schools within the Division. Outside of the Educational arena, Dr. Stoddard served as the Senior Manager of the Innovation and Improvement Unit, Research and Innovation Branch, within the Government of Alberta. In this role, she established and led a unit responsible for a variety of initiatives that involved partnerships with other Ministries, community agencies, private sector organizations, provincial associations, and academic institutions, all with the aim of engaging communities and individuals to improve support and services to Alberta’s vulnerable children, youth, and families. During this role, she was a recipient of the Premier’s Award of Excellence.

At the international level, Dr. Stoddard served as a Board of Director for the Association for Supervision and Curriculum Development (ASCD), a global organization comprised of 115,000 members in more than 128 countries, working to pursue excellence in learning, teaching and leading. As a result of meeting with education and government officials in numerous countries, she is fully aware of issues in education that are international in scope which will enhance our ability to potentially contribute to positive educational outcomes on a global level.

“I am excited to be a part of Eyecarrot and integrating Binovi into practice. Preliminary research suggests that vision therapy can be used to improve reading fluency, reading comprehension and other educational outcomes. For far too long, education has been working in a silo to try to address educational challenges. The impact of integrating medical and educational research, to support success for all students, has the potential to be transformational,” stated Dr. Sandra Stoddard B.Ed, M.Ed, PhD, Eyecarrot Scientific Advisory Board.

“Dr. Stoddard’s wealth of experience in integrating educational theory into practice will be an asset to the company as we collaborate, to improve educational outcomes for students,” commented Eyecarrot CEO Adam Cegielski.

Vision is an integral component of learning, and I look forward to working with Dr. Stoddard on optimizing the transfer of visual abilities to the educational environment”, noted Dr. Leonard Press, Chief Scientific Officer of Eyecarrot.

In addition to the affirmation of Dr. Dyck and Dr. Stoddard to the Scientific Advisory Board, Mr. Terry Booth, Founder and former CEO of Aurora Cannabis (ACB), was appointed as the Company’s Executive Chairman. Mr. Booth skillfully raised Aurora from its infancy into one of the world’s largest and fastest growing cannabis companies, valued at $18B at its peak, with a focus on providing high-quality medical and adult usage cannabis and inspiring better days for medical and recreational consumers around the world. Mr. Booth is instrumental in coordinating the contributions of Dr. Jason Dyck and Dr. Sandra Stoddard to the expansion of Eyecarrot’s Binovi Platform.

The company is driven to leveraging expert knowledge as part of the development, expansion, and delivery of the Binovi Platform to clients in all industries, from education, to sports, to optometry, and beyond.

Please visit https://www.eyecarrot.com/investors/ for additional information on the Company.

About Eyecarrot Innovations Corp (EYC)

Eyecarrot is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Investor Relations

Email: [email protected]arrot.com
Toll-free: 1 (844) 866-6162
https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com. The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Eyecarrot $EYC.ca Announces Closing of Financing $EYPT $KALA

Posted by AGORACOM-JC at 5:23 PM on Tuesday, June 9th, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announced the closing of the previously announced non-brokered private placement for total proceeds of C$1 million
  • The Company issued a total of 7,843,137 units at C$0.1275 per unit, each unit comprised of one common share of the Company and one common share purchase warrant

Toronto, New York – June 9, 2020 – Eyecarrot Innovations Corp. (TSXV:EYC) | (OTC:EYCCF) | (2EYA:GR) is pleased to announce the closing of the previously announced non-brokered private placement for total proceeds of C$1 million. The Company issued a total of 7,843,137 units at C$0.1275 per unit, each unit comprised of one common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Share (each, a “Warrant Share”) at an exercise price of C$0.25 per Warrant Share at any time until June 8, 2022. The warrants are subject to an acceleration clause whereby if the common share price is equal to or greater than C$0.50 for a period of 5 consecutive trading days (at any time at or following the expiry of the four months resale restriction period), the Company may, by notice to the warrant holder reduce the remaining exercise period applicable to the warrants to not less than 30 days from the date of such notice.

Insiders participated in the private placement acquiring an aggregate of 1,435,300 units on the same basis as other subscribers. The participation in the private placement by insiders of the Company constitutes a “related party transaction” as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on exemptions from the formal valuation and minority approval requirements under MI 61-101. The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as the fair market value of the private placement in so far as the private placement involved interested parties did not exceed 25% of the Company’s market capitalization.

The securities issued in connection with the private placement are subject to a four-month hold period expiring on October 10, 2020.

The proceeds of the private placement will be used for working capital purposes and further development of the Company’s product and service offerings.

About Eyecarrot Innovations Corp (EYC)

Eyecarrot is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CLIENT FEATURE: Eyecarrot Innovations $EYC.ca Creating Faster Brains Through Stronger Eyes $EYPT $KALA

Posted by AGORACOM-JC at 5:54 PM on Tuesday, June 2nd, 2020
http://www.smallcapepicenter.com/eyc%20square.png

EYC: TSX-V

Trusted and used by some of the world’s top professional sports teams, including:

Why Eyecarrot?

  • Eyecarrot Has Already Started Commercializing Its Vision Therapy Platform
  • Company’s Vision Therapy Products Used In:
    • Over 1,500 Practices
    • 20 Countries
  • Flagship “Binovi” Is State-Of-The-Art Platform
    • Measures 14 Key Vision Skills
    • Essential For Maximizing Brain Performance
    • Shipped Over 400 Binovi Units (April 2020)
    • Goal Is 2,500 Binovi Units (End Of 2020)
  • Signed Sports Vision Partnership With Eli Wilson Goaltending
    • World Leader In Goaltending Development
    • 600 Active Goaltending Camp Participants
    • 50,000 Global Aspiring Goaltenders
  • Closed Major Financing In Q1 2020
  • Eyecarrot is now well positioned to further commercialize and capitalize on massive demand for Vision Therapy and Training For Athletes and Education

Serial Entreprenuer and Former Aurora Cannabis CEO, Terry Booth, Joins Eyecarrot as Executive Chairman

  • Mr. Booth was one of the 2 original founders of Aurora Cannabis Inc. In 2013, he personally provided over $3.0 million in start-up capital to the building of a new from the ground up high quality purpose-built medical cannabis production facility in Mountain View County.
  • Appointed CEO in December 2014, he has skillfully raised Aurora from its infancy into one of the world’s largest and fastest growing cannabis companies, valued at $18B at its peak

THE MARKET OPPORTUNITY

  • Vision Therapy captures 3% of a $36B Yearly Vision Market today
  • Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
  • Sights are set on disrupting the sports performance industry in 2020 while receiving engagement from leaders within the human performance – sport performance industry
  • The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
  • Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022

WATCH OUR RECENT INTERVIEW

Eyecarrot Innovations is an advertising client of AGORA Internet Relations Corp.

VIDEO: Aurora Cannabis $ACB Founder, Terry Booth, Is Taking Eyecarrot Vision Therapy Global $EYC.ca / $EYCCF

Posted by AGORACOM-JC at 6:15 PM on Thursday, May 28th, 2020
http://www.smallcapepicenter.com/eyc%20square.png

Eyecarrot Innovations (EYC:TSXV) is a Vision Therapy and Training Company that goes well beyond fixing eyes that simply can’t read letters on an eye chart. That’s what your optometrist does when they prescribe glasses.

What Eyecarrot does is far more exciting and groundbreaking. Without getting scientific, Eyecarrot delivers higher performing brains by optimizing the performance of your eyes.  The result is a faster brain through stronger eyes, which creates quite the edge for the world’s best athletes and explains why their client list includes:

  • Dallas Stars (NHL)
  • Chicago Cubs (MLB)
  • Sporting KC (MLS)
  • Tennis Canada
  • Showcased During NFL Scouting Combine
  • Eli Wilson Goaltending – The World Leader In Hockey Goaltending Development

BUT NEW EXECUTIVE CHAIRMAN, TERRY BOOTH, HAS A DIFFERENT AND BIGGER VISION (PARDON THE PUN) FOR EYECARROT – GLOBAL CHILDREN  

When Terry’s daughter was 1 years old, she developed eye problems that could only be treated by patching -  something he says would be considered “barbaric” today.  Terry discovered that 1 in 4 kids (not a typo) have vision problems beyond those treatable by an optometrist.  This was a global, epidemic without a solution that often leads to kids losing critical learning time and self-confidence by Grade 3.    

Fast Forward 30 years to about 4 weeks ago and Terry finally found the solution – Eyecarrot – but not before he and his science team put CEO Adam Cegielski and the Company through the ringer.  When the due diligence was complete, Terry Booth was all in….  

… And he’s bringing his entire science, government and finance network to the table to bring Eyecarrot to children around the world.    

Turn off NetFlix. Ignore your social media notifications.  Grab your favourite beverage, call a couple of friends and watch this interview … twice.  

Can’t spare enough time to stare at a screen?

Take AGORACOM with you in your car or on your walk by Podcast on Apple, Google, Spotify or your favourite podcaster.

Eyecarrot $EYC.ca Affirms Appointment of Dr. Leonard Press as Chief Scientific Officer $EYPT $KALA

Posted by AGORACOM-JC at 7:16 AM on Thursday, May 28th, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announces the appointment of Dr. Leonard Press to Chief Scientific Officer
  • Dr. Press has contributed to the Company as its Director of Global Education supporting the development resources available to vision professionals through Binovi Academy and the Binovi Platform

TORONTO, ON and NEW YORK, NY / May 28, 2020 / Eyecarrot Innovations Corp (TSXV:EYC)(QTCQB:EYCCF)(FRA:2EYA:GR] announces the appointment of Dr. Leonard Press to Chief Scientific Officer. Dr. Press has contributed to the Company as its Director of Global Education supporting the development resources available to vision professionals through Binovi Academy and the Binovi Platform. Through his appointment, he will lead the Scientific Advisory Board and all scientific development efforts including the expansion of Speed of Stereopsis, established by his predecessor Dr. Selwyn Super, who passed away earlier this year.

Dr. Leonard Press is a graduate of the Pennsylvania College of Optometry, where he was a member of the Gold Key International Optometric Honor Society. He completed his Residency program in Pediatric Optometry at The Eye Institute of the Pennsylvania College of Optometry in Philadelphia, and formerly served as Chief of the Pediatric Unit of The Eye Institute. Dr. Press was recruited to the State University of New York, State College of Optometry, to serve as Chief of the Vision Therapy Service, where he was Associate Professor of Clinical Optometry for 15 years. Patients of all ages with problems related to vision development, visual processing, learning disabilities, and dyslexia are referred to Dr. Press by a wide variety of professionals through his consulting practice in Lakewood, New Jersey. He works extensively with occupational therapists, educators, and parent groups in helping parents understand the relationship between vision and learning, and opportunities for therapy to help children succeed.

“Dr. Selwyn Super was a gentleman and scholar whose foresight helped set the scientific tone for Eyecarrot and Binovi. His vision and thought processes had a significant influence on my thinking and career, as well as on the careers of many contributors to our field. I look forward to carrying on and expanding his scientific legacy as we continue to develop the Binovi suite of concepts and products.” stated Dr. Leonard Press, OD, FAAO, FCOVD

Additionally, Dr. Press has been recognized internationally for his work in the field of learning-related vision problems. He was a co-author of the Clinical Practice Guidelines in this area for the American Optometric Association and is the author of a monograph from the Optometric Extension Program on Computers and Vision Therapy Programs. He is the author of three major textbooks on vision which act as the primary reference used by therapists and doctors from around the world who are preparing for board certification in vision therapy through the College of Optometrists in Vision Development (COVD). Dr. Press served as President of the College of Optometrists in Vision Development, and formerly served on the examining board which conducts board certification. He is also a Diplomate in the Pediatric Optometry/Binocular Vision and Perception Section of the American Academy of Optometry, and the only doctor in New Jersey with specialty certification through both of these prestigious organizations.

Dr. Press served as a consultant on visual disabilities for the National Board of Medical Examiners (NBME), where he reviewed requests for test accommodations on the examinations that certifies MDs to practice Medicine in the United States. Candidates submit a request for modification of their computer monitor, extra time, or test breaks, based on supporting documentation of any visual disabilities not fully corrected by glasses or contact lenses. Many children in special education environments face similar issues in terms of Section 504 accommodations for schoolwork or standardized testing. He has lectured extensively on these subjects in the United States and abroad.

The recipient of numerous awards for his research, writing, and clinical work, Dr. Press has received the Scientific Achievement Award from the New Jersey Society in both 1995 and in 2002. He received the Skeffington Award for Excellence in Optometric Writing from the College of Optometrists in Vision Development in 1992 and was honored by his peers as Optometrist of the Year by the New Jersey Society of Optometric Physicians, previously serving as President of the organization. He was honored as the Alumnus of the Year of the Pennsylvania College of Optometry in 2003, which cited him for his outstanding contributions in the field of children’s vision and vision-related learning problems.

“Our partnership with Dr. Press has already proven to be a fruitful one for both parties, and with the unfortunate passing of Dr. Selwyn Super earlier this year, we saw it fit to invite him to take his place as a key part of the continued development of the Binovi Platform. Dr. Press’ credentials, accomplishments, and experience speak for themselves and will be a great asset to the Company moving forward. We look forward to continue working with Dr. Press as Binovi grows,” commented Adam Cegielski, President and CEO.

The Company also announces it has retained Generation IACP Inc. (“Generation“) to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of its Common Shares. Under the agreement between Generation and the Company (the “Generation Agreement“), the Company has agreed to initially pay Generation a fee of C$7,500 plus applicable taxes, per month. Generation will not receive any Common Shares or options as compensation. Generation does not currently own any securities of Eyecarrot Innovations Corporation; however, Generation and its clients may acquire a direct interest in the securities of the Company. Eyecarrot Innovation Corporation and Generation are unrelated and unaffiliated entities. Generation is a member of the Investment Industry Regulatory Organization of Canada and a member firm of the Toronto Stock Exchange and the TSX Venture Exchange. The initial term of the Generation Agreement will last 6 months, and such term will be automatically renewed for subsequent 6-month periods unless terminated earlier by 30 days’ prior written notice.

About Eyecarrot Innovations Corp

Eyecarrot is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

On behalf of the Board of Directors

Adam Cegielski
President | CEO

Investor Relations

Email: [email protected]
Toll-free: 1 (844) 866-6162
https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Serial Entreprenuer and Former Aurora Cannabis $ACB CEO, Terry Booth, Joins Eyecarrot $EYC.ca as Executive Chairman $EYPT $KALA

Posted by AGORACOM-JC at 3:04 PM on Thursday, May 21st, 2020
http://www.smallcapepicenter.com/eyc%20square.png
  • Announced the appointment Aurora Cannabis (TSX-ACB) Founder and former CEO, Mr. Terry Booth, to the Company as Executive Chairman.
  • Mr. Booth was one of the 2 original founders of Aurora Cannabis Inc. In 2013, he personally provided over $3.0 million in start-up capital to the building of a new from the ground up high quality purpose-built medical cannabis production facility in Mountain View County.
  • Appointed CEO in December 2014, he has skillfully raised Aurora from its infancy into one of the world’s largest and fastest growing cannabis companies, valued at $18B at its peak

Toronto, New York -  May 21st, 2020Eyecarrot Innovations Corp (TSXV:EYC) | (OTC:EYCCF) | (2EYA:GR), is pleased to announce the appointment Aurora Cannabis (TSX-ACB) Founder and former CEO, Mr. Terry Booth, to the Company as Executive Chairman. Mr. Booth was one of the 2 original founders of Aurora Cannabis Inc. In 2013, he personally provided over $3.0 million in start-up capital to the building of a new from the ground up high quality purpose-built medical cannabis production facility in Mountain View County. This facility was the first in the world to be certified as 100% EU GMP compliant for the production of Medical Cannabis. Appointed CEO in December 2014, he has skillfully raised Aurora from its infancy into one of the world’s largest and fastest growing cannabis companies, valued at $18B at its peak, with a focus on providing high-quality medical and adult usage cannabis and inspiring better days for medical and recreational consumers around the world.

A visionary and passionate leader, Terry has a deep knowledge of highly regulated environments. He was instrumental in Aurora receiving its initial licensing and approval from Health Canada to produce medical cannabis, as well as building the Company’s state of the art cultivation facility Aurora Sky. With this strong entrepreneurial vision running through the entire company, Terry has overseen the company’s organic growth as well as its expansion through acquisitions of companies, all of which were successfully integrated into the parent company.

“I am beyond excited to be a part of a new technology platform that will focus on improving vision globally. In particular, improving youth vision through this revolutionary technology that has not only been proven but is being used by world class athletes to improve their binocular vision, balance, and strength. Our product will set the standard in this nascent industry on a global basis,” commented Terry Booth, Executive Chairman

Uniquely skilled at seizing M&A opportunities, (over 30 transactions and acquisitions in the last 5 years) Terry also has more than 25 years of experience in creating, growing and leading companies in highly regulated industries. Terry currently sits on the board of Aurora Cannabis, Quinsam Capital, and Psyched Wellness and has sat on the board of other organizations, including Radient Technologies and Alcanna (formerly Liquor Stores N.A.). Terry has also served as President/CEO of Superior Safety Codes Inc, which was recognized as one of Canada’s top 50 fastest-growing companies. Terry joins Eyecarrot with an established track-record of transformational leadership and a purpose to impact Global Health and Education.

“We are absolutely thrilled to add the expertise and experience of a member of Terry’s caliber, and the team at Eyecarrot firmly believes that this will set our path moving forward. With his proven track record in building and growing businesses in technologically and medically innovative fields, Terry brings an unsurpassed wealth of knowledge to our dedicated and motivated team. He has the unique ability to move mountains when it comes to policy at the national and international level, as well as an incredible track record in capital markets. We’re excitedly looking forward to working together to accomplish our goals, bring value to our investors, and ultimately improve human performance,” commented Eyecarrot Founder and CEO Adam Cegielski.

In connection with these corporate changes, the Company would also like to announce it as arranged a non-brokered private placement to raise up to $1 million through the issuance of up to 7,843,137 units at a price of $0.1275 per unit, subject to the approval of the TSX Venture Exchange.

Each unit will comprise one common share and one share purchase warrant. Each warrant will entitle the holder to acquire a further common share at a price of $0.25 per share for a period of 24 months, subject to an acceleration clause whereby if the closing price of the Company’s shares is equal to or greater than $0.50 per share for a period of five consecutive trading days (at any time following the expiry of the four month resale restriction period), the Company, may, by notice to the warrant holder, reduce the remaining exercise period of the warrants to not less than 30 days from the date of such notice. The proceeds of the placement will be utilized for the further development of the Company’s products and for general working capital purposes. Mr. Booth is expected to subscribe for up to 1,960,785 units of the financing.

The Company also announces the grant of an aggregate of 2,500,000 stock options at an exercise price of $0.17 per share for a period of five years to directors, officers, employees and consultants, of which 500,000 stock options will be granted to Mr. Booth.

Dr. John Flanagan has resigned from the Board of Directors of the company to make room for Mr. Terry Booth, and will now be the first member of the company’s Scientific Advisory Board.

Please visit https://www.eyecarrot.com/investors/ for additional information on the Company.

About Eyecarrot Innovations Corp (EYC)

Eyecarrot is a human performance technology company that has developed Binovi, a hardware and software-centered platform. Binovi combines hardware, software, specialized expert knowledge, and unique big data insights in order to deliver customized one-on-one training and treatment. Binovi is designed for vision optimization and the enhancement of skills related to human performance. We are working together under a common banner to help neuro-optometry, vision rehabilitation, and vision performance professionals gain measurable results in less time, and with less effort.

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Investor Relations

Email: [email protected]

Toll-free: 1 (844) 866-6162

https://www.eyecarrot.com/investors/

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CLIENT FEATURE: Eyecarrot Innovations $EYC.ca Creating Faster Brains Through Stronger Eyes $EYPT $KALA

Posted by AGORACOM-JC at 6:11 PM on Wednesday, May 20th, 2020
http://www.smallcapepicenter.com/eyc%20square.png

(TSXV:EYC) | (OTC:EYCCF) | (2EYA:GR)

Trusted and used by some of the world’s top professional sports teams, including:

  • Eyecarrot Has Already Started Commercializing Its Vision Therapy Platform
  • Company’s Vision Therapy Products Used In:
    • Over 1,500 Practices
    • 20 Countries
  • Flagship “Binovi” Is State-Of-The-Art Platform
    • Measures 14 Key Vision Skills
    • Essential For Maximizing Brain Performance
    • Shipped Over 400 Binovi Units (April 2020)
    • Goal Is 2,500 Binovi Units (End Of 2020)
  • Signed Sports Vision Partnership With Eli Wilson Goaltending
    • World Leader In Goaltending Development
    • 600 Active Goaltending Camp Participants
    • 50,000 Global Aspiring Goaltenders
  • Closed Major Financing In Q1 2020
  • Eyecarrot is now well positioned to further commercialize and capitalize on massive demand for Vision Therapy and Training For Athletes and Education

THE MARKET OPPORTUNITY

  • Vision Therapy captures 3% of a $36B Yearly Vision Market today
  • Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
  • Sights are set on disrupting the sports performance industry in 2020 while receiving engagement from leaders within the human performance – sport performance industry
  • The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
  • Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022

AS FEATURED ON BTV:

Eyecarrot Innovations is an advertising client of AGORA Internet Relations Corp.

MEDIA: Eyecarrot $EYC.ca CEO Adam Cegielski Featured on Capital Ideas TV – Company Technology Trusted By The Chicago Cubs, Dallas Stars and Many Others $EYPT $KALA

Posted by AGORACOM-JC at 4:59 PM on Monday, May 11th, 2020
http://www.smallcapepicenter.com/eyc%20square.png

Eyecarrot Goes Beyond Fixing Eyes That Simply Can’t Read Letters On An Eye Chart

THE MARKET OPPORTUNITY

  • Vision Therapy captures 3% of a $36B Yearly Vision Market today
  • Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
  • Sights are set on disrupting the sports performance industry in 2020 while receiving engagement from leaders within the human performance – sport performance industry
  • The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
  • Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022